Washington GLP-1 Med Spa Compliance 2026

Washington flips the usual med spa compliance problem on its head. In most states the hardest question in a weight loss programme is who is allowed to be the clinician, and answering it means collaborative agreements, chart-review percentages, and a physician whose availability has to be mapped. Washington largely removes that question: an advanced registered nurse practitioner with prescriptive authority is a fully independent prescriber, so a nurse-led weight loss practice here is legitimate and structurally simple.

That is good news, and it is also why Washington programmes fail in a particular way. When staffing is easy, operators stop thinking about what is not — where the drug comes from, whether the evaluation behind the prescription would survive a records request, and whether a clinician was involved at each dose escalation. For the federal baseline, our GLP-1 med spa compliance complete guide covers the national picture, and the med spa regulations by state reference places Washington beside Oregon, Idaho, and California.

Why a Washington GLP-1 Program Answers to Three Agencies

Washington issues no med spa facility licence. No state office inspects the business or certifies a weight loss programme, so compliance attaches entirely to individual credentials, the drug supply chain, and the records. Three agencies each own a piece.

The Washington Medical Commission

The Medical Commission regulates physicians and physician assistants and sets the standards deciding whether a prescription rests on an adequate evaluation. Worth naming what it does not govern here: WAC 246-919-606, the rule that dominates Washington injectables compliance, applies to nonsurgical medical cosmetic procedures. A GLP-1 prescribed for weight management is therapeutic, not cosmetic — so citing 246-919-606 in a weight loss protocol is a tell that the protocol was copied from an injectables binder.

The Washington State Board of Nursing

The Board of Nursing — renamed in 2023 from the Nursing Care Quality Assurance Commission, the NCQAC most binders still name — governs ARNPs, RNs, and LPNs. It grants and polices ARNP prescriptive authority and decides what a nurse may do with a prescribed injectable. Its advisory opinions issue under WAC 246-840-800 and are explicitly not legally binding — which does not make them optional reading, since a nurse practising against a published Board position is defending their licence to the Board that published it.

The Pharmacy Quality Assurance Commission

The third agency is the one weight loss programmes never think about until a letter arrives. It licenses pharmacies, including nonresident pharmacies shipping legend drugs into Washington, with its rules now consolidated in chapter 246-945 WAC. If your compounded semaglutide ships in from another state, this Commission — not the Medical Commission — has jurisdiction over that end of your supply chain.

Who Can Prescribe GLP-1 Medications in Washington

Prescribing is the decision — candidacy, drug, starting dose, titration plan. Everything downstream executes it, so be exact about who may make it.

Physicians (MD and DO)

Verdict: yes, on their own authority. A Washington-licensed physician or osteopathic physician evaluates the patient, determines whether a GLP-1 receptor agonist is appropriate, prescribes it, and owns the monitoring plan. Because GLP-1s are not controlled substances, DEA registration is irrelevant to prescribing semaglutide or tirzepatide — it becomes relevant the moment a programme adds phentermine, a Schedule IV drug.

ARNPs and full prescriptive authority — Washington's distinctive angle

Verdict: yes, independently. This is the most important fact about running a weight loss programme here. Under RCW 18.79.250 and WAC 246-840-300, an ARNP is a licensed independent practitioner who diagnoses and manages acute, chronic, and complex conditions without physician oversight and without a collaborative agreement — no transition period, no minimum supervised hours, nothing to file first.

Obesity and metabolic disease sit squarely inside the scope of an appropriately prepared ARNP's population focus, so an ARNP may take the intake, order baseline labs, diagnose, prescribe, set the titration schedule, and manage adverse effects — the entire clinical arc — with no physician involved. Note the title, too: Washington says ARNP, not APRN or NP.

Prescriptive authority is a separate credential to verify

Full practice authority is not a prescription pad. The Board of Nursing grants ARNP prescriptive authority separately under WAC 246-840-410, requiring an active unrestricted licence plus thirty contact hours of pharmacology education, generally completed within the two years before applying, with an extra fifteen hours of pharmacotherapeutics CE at each renewal. Verify that authority on the credential lookup, not from a job title: an ARNP without it can practise nursing fully and cannot write the prescription your programme depends on.

Physician assistants, and who cannot prescribe at all

PAs: yes, through a participating physician. A Washington PA prescribes within the scope of their practice agreement and their participating physician's practice, so the agreement has to actually cover metabolic and obesity management — authority follows the agreement, not the training. Nobody else prescribes: not RNs, LPNs, medical assistants, estheticians, health coaches, nutritionists, unlicensed owners, or a business entity. A programme whose intake is triaged by a coach who routes patients into pre-set dosing tiers has moved the prescribing decision to an unlicensed person no matter whose name signs the order.

Who Can Administer a GLP-1 Injection in Washington

Administration is a wider door than prescribing, because a GLP-1 dose is an ordinary subcutaneous injection of a prescribed drug rather than a cosmetic procedure.

Registered nurses, LPNs, and medical assistants

RNs: yes, on a valid patient-specific order. Administering prescribed medications is core registered nursing practice under chapter 18.79 RCW. An RN may draw up and administer a dose, teach self-injection, take the interval history, and escalate to the prescriber — but may not decide this patient is a candidate, choose between semaglutide and tirzepatide, set the starting dose, or authorise the next titration step. An LPN may administer within LPN scope, interdependently under an RN's direction and dependently under a physician, PA, or other authorized practitioner.

A medical assistant-certified may perform subcutaneous injections when delegated and supervised under chapter 18.360 RCW — a better position than the same MA occupies in cosmetic injectables, where WAC 246-919-606 excludes them outright. The limits still bite: RCW 18.360.060 bars protocol-based delegation involving clinical judgment or medications other than vaccines, so the delegation must be patient-specific and supervised. If your model depends on MA injectors, confirm it in writing with the Department of Health first.

Why WAC 246-919-606 is the wrong rule to cite here

Operators who came up through injectables reflexively reach for the cosmetic delegation rule, and it does not apply. WAC 246-919-606 governs cosmetic procedures, with its written-office-protocol requirement, closed delegate list, and thirty-minute physician response standard. That cuts both ways: you do not owe the thirty-minute standard for a weight loss visit, and you cannot borrow the delegate list to justify your staffing either. General nursing scope and chapter 18.360 RCW govern instead.

Patient self-injection and the teaching visit

Most Washington GLP-1 programmes are self-injection programmes, which quietly moves the compliance weight onto teaching and documentation. Record who taught the technique and when, the method taught, what the patient was told about storage, sharps disposal, missed doses, and adverse effects, and what teach-back confirmed. Multidose vials deserve particular care: FDA adverse-event reporting on compounded GLP-1s is thick with dosing errors by patients drawing from vials, some requiring hospitalisation.

The Good-Faith Exam and Telehealth Prescribing in Washington

Washington has no rule using the phrase "good faith exam," and a surprising number of operators read that silence as meaning no requirement exists. It plainly does — assembled from prescribing law and standard-of-care rules rather than stated in one tidy place.

What the encounter must establish

A GLP-1 is a prescription drug, and a lawful prescription requires a legitimate practitioner-patient relationship and an evaluation adequate to support the diagnosis and the drug chosen. For a weight loss programme that means a real clinical encounter with a prescriber covering weight and BMI history, comorbidities, prior weight loss attempts, current medications and interactions, relevant history, and the contraindications the prescribing information names.

Washington allows telehealth, and holds it to the same standard

Verdict: no in-person visit is required for a non-controlled prescription in Washington. The state holds telemedicine to the same standard of care as in-person practice — not a lower standard, and not a higher one. A synchronous audio-video encounter with a Washington-licensed prescriber, with documented telehealth consent, verified patient identity, a chart entry at ordinary clinical depth, and a documented route to follow-up and emergency care, supports a first-visit GLP-1 prescription.

What Washington will not accept is the model the sector is being scrutinised for: an online questionnaire auto-approved with no clinician encounter, a prescriber signing a batch of orders for patients they never assessed, or a standing order pre-approving everyone who books. None is an evaluation; each is a record that no evaluation happened.

Where controlled substances change the analysis

GLP-1 receptor agonists are not controlled substances, so federal telemedicine rules for controlled prescribing do not touch a semaglutide prescription. They do touch phentermine, a Schedule IV drug many programmes carry alongside GLP-1s. Those flexibilities have been extended by temporary DEA rules rather than made permanent, and the expiry has moved more than once — confirm the operative date before relying on it.

Compounded Semaglutide and Tirzepatide: What Changed and What Is Unsettled

This is where the money and the risk both concentrate. The compounded-GLP-1 model that built thousands of programmes no longer exists in the form operators remember, and the federal picture kept moving through 2026.

The shortage era ended

Compounded copies were lawful at scale for one reason: the branded drugs sat on the FDA drug shortage list, and the FDA exercised enforcement discretion accordingly. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025, then wound the discretion down on a published schedule:

• 503A state-licensed pharmacies lost enforcement discretion for tirzepatide in March 2025.
• 503A pharmacies lost it for semaglutide on 22 April 2025.
• 503B outsourcing facilities lost it for semaglutide on 22 May 2025.

Industry litigation failed to obtain preliminary relief and the deadlines held. Our guide to compounded GLP-1s and 503A versus 503B sourcing walks the chronology in more detail.

What still qualifies as lawful compounding

Compounding did not become illegal — the shortage-era shortcut did. What survives is ordinary compounding law: a prescription for an identified individual patient, a documented clinical determination that the preparation is necessary for that patient rather than merely cheaper, and a licensed compounder. An intolerance to an inactive ingredient in the approved product, or a dose the approved presentations cannot deliver, can support one. What does not qualify is the pattern regulators see: standard dosing tiers, volume orders, or a clinical-need note identical in every chart — which documents a business model rather than a clinical need.

The April 2026 503B bulks proposal — genuinely unsettled

The live question, and one we would rather flag than pretend is closed: on 30 April 2026 the FDA proposed to leave semaglutide, tirzepatide, and liraglutide off the 503B bulk drug substances list, having found no sufficient clinical need for outsourcing facilities to compound them from bulk substances while approved products are available. The comment period closed 30 July 2026, and as of publication the FDA had announced no final determination. If finalised as proposed, it would close bulk-substance compounding of the three major GLP-1s essentially permanently rather than pending a shortage. Nothing about the pause makes a volume compounding programme safe — watch the docket, with a plan that survives finalisation.

503A vs 503B Sourcing for a Washington Practice

Sourcing is the part of a Washington GLP-1 programme with the least state-specific guidance and the most state-specific exposure. Get the vocabulary exact, because contracts and marketing blur it.

What each facility type actually is

A 503A pharmacy is a state-licensed pharmacy compounding pursuant to a prescription for an individually identified patient. It does not register with the FDA as an outsourcing facility, need not meet current good manufacturing practice, and cannot lawfully compound for office stock. A 503B outsourcing facility registers with the FDA, must comply with CGMP, is FDA-inspected, and may compound without patient-specific prescriptions — but only from bulk substances the FDA has found a clinical need for, which is exactly the list the April 2026 proposal addresses. Neither is a manufacturer, and neither produces an FDA-approved drug.

The Washington wrinkle: nonresident pharmacy licensure

Here is the state-law point most Washington programmes miss. A pharmacy outside Washington that ships, mails, or delivers legend drugs to patients here must hold a nonresident pharmacy licence from the Pharmacy Quality Assurance Commission under RCW 18.64.350 through RCW 18.64.400, and non-compliance can draw suspension or revocation, or a fine of up to one thousand dollars per violation. The practical step takes five minutes and almost nobody does it: look up every pharmacy in your supply chain on the Washington credential search. A slick portal and same-week shipping tell you nothing about licensure — and if the pharmacy is not licensed to ship here, your practice is the visible end of an unlawful channel.

Research peptides are not a sourcing option

Vials sold as "research use only" or "not for human consumption," peptides from a chemical supplier, and grey-market imports are not compounded drugs and are not lawfully administrable to patients. No protocol, consent form, or waiver makes this compliant, and a practice administering them has an unlicensed-drug problem, a standard-of-care problem, and an uninsurable-act problem at once.

What a defensible Washington programme sources

In descending order of defensibility: the FDA-approved product through a licensed pharmacy, which carries approved labelling and no compounding argument to make; a patient-specific compounded preparation from a Washington-licensed 503A pharmacy where the chart documents an individual clinical need; and, where lawful for the substance, a registered 503B facility holding Washington nonresident licensure. Keep the sourcing rationale in the chart, not a vendor folder.

Patient Screening, Eligibility, and Contraindications

Washington sets no eligibility criteria for GLP-1 therapy by rule. That does not make criteria optional — the standard of care and your own written protocol supply them, and a protocol you wrote and did not follow is the worst available position.

What eligibility criteria a protocol should state

A written screening protocol should say in advance, in specific terms, who the programme treats: the anthropometric and comorbidity thresholds used, how weight history and prior pharmacotherapy are assessed, what baseline data must exist before a first prescription, and what findings send a patient to their primary care clinician instead. Criteria written as clinical decision rules can be audited and followed; criteria written as marketing copy cannot.

Contraindications and cautions to screen for and record

The record should show the prescriber actively looked for the contraindications and warnings in the approved prescribing information for the product in question, rather than that the patient failed to volunteer them. Depending on the agent, the areas typically requiring attention include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, prior serious hypersensitivity to the drug, pregnancy and pregnancy planning, history of pancreatitis, gallbladder disease, severe gastrointestinal disease including gastroparesis, diabetic retinopathy, renal impairment with volume depletion risk, history of suicidal ideation, and concurrent insulin or sulfonylurea therapy.

Two operational points matter as much as the list. Delayed gastric emptying has made anaesthesia and sedation planning a live issue, so a practice that also performs procedures needs a documented pathway. And a negative screen is a finding: a blank field reads as a question never asked.

What the screening record must show

At minimum: who performed the evaluation and their credential, the data the eligibility decision rested on, the contraindication review, the consent conversation, the product and source selected with the reason, the starting dose and titration plan, and the follow-up interval. If the chart cannot answer "why this patient, this drug, this dose, from this source," it will not answer a reviewer either.

Monitoring, Titration, and Follow-Up

Monitoring is where a Washington programme is most likely to be structurally non-compliant while looking entirely normal from the front desk. Nothing visible goes wrong; the record simply never shows a clinician at the decision points.

Baseline before the first dose

Whatever baseline your protocol specifies should exist in the chart before the first dose leaves the building — dated, reviewed, and attributed. The common failure is not missing labs but the sequence: labs ordered at the first visit, the first dose given the same day, results reviewed by nobody in particular a fortnight later. If your protocol says baseline data are required before initiation, that sentence is the standard you are held to.

The titration window

Dose escalation is a prescribing decision every single time. Each step needs a documented clinician assessment of tolerance and response, and an order reflecting the decision made — not a schedule that advances automatically unless a patient complains. This is where staff-run programmes drift into unlicensed practice: a nurse or assistant who moves a patient up a tier because the calendar says so has made the prescriber's decision.

Adverse-event vigilance and escalation

Each follow-up should record tolerance, gastrointestinal symptoms, hydration, any concerning abdominal or biliary symptoms, weight trajectory, and adherence — plus what the patient was told about when to stop and seek care. The programme needs a written escalation pathway naming who is contacted, how quickly, and what happens after hours, and a practice that dispensed a compounded vial is expected to have an adverse-event reporting route rather than an anecdote.

Recordkeeping a Washington GLP-1 Program Must Keep

Washington's oversight of weight loss programmes is documentary almost end to end. Nobody inspects the premises; somebody eventually reads the file. Build three files and keep them current.

Clinical records

• The prescriber's evaluation and diagnosis per patient, with the eligibility rationale and contraindication review.
• A patient-specific order for every dose administered, naming drug, strength, route, and dose.
• Informed consent covering the drug, its risks, and off-label or compounded status — plus telehealth consent and identity verification where the encounter was remote.
• A titration record showing a clinician assessment and order behind each dose change, injection teaching documentation, and adverse event records.

Sourcing and drug-handling records

• Pharmacy licence verification for every supplier, including Washington nonresident licensure for out-of-state shippers.
• Where compounded, the documented individual clinical need in that patient's chart — not a template sentence.
• Lot numbers, beyond-use dates, and cold-chain logs, plus invoices that reconcile to patient-specific prescriptions rather than bulk orders.

Structural records

• Current credential verification for every clinician — and for ARNPs, explicit evidence of prescriptive authority.
• The practice agreement for any PA, confirming it covers metabolic and obesity management.
• The written programme protocol: eligibility, contraindications, baseline, titration, monitoring, escalation, and adverse-event reporting — with a dated review log, the cheapest evidence the programme is actively governed rather than inherited.
• Delegation documentation for any MA or LPN administering doses, and dated training records per staff member and task.

What Gets a Washington Practice Disciplined

Washington's enforcement posture in aesthetics and weight loss is quieter than California's and more administrative than criminal — but it is active, public, and arrives from several directions at once.

Unlicensed practice

Under RCW 18.130.190, the Secretary of Health may issue a cease-and-desist order against unlicensed practice — including a temporary order without a prior hearing where delay would irreparably harm the public — and may impose a civil fine of up to one thousand dollars for each day of unlicensed practice. Criminally, it is a gross misdemeanour, and each subsequent violation a class C felony under chapter 9A.20 RCW. The Department of Health publishes its charges, and the archetype is a non-medical business drifting into a medical procedure — a pattern a programme staffed by coaches fits precisely.

Discipline across three agencies

For licensed practices the likelier exposure is unprofessional conduct under RCW 18.130.180, which reaches prescribing without an adequate evaluation, incompetence or negligence, misrepresentation in advertising, and failure to keep adequate records. The Medical Commission acts against physicians and PAs, the Board of Nursing against ARNPs, RNs, and LPNs — and both can act on the same facts, so a programme where the ARNP prescribed without an evaluation and the RN administered without a valid order generates two files.

Advertising claims that draw a citation

Marketing is regulated conduct: misrepresentation in advertising is unprofessional conduct under RCW 18.130.180, reachable against the clinician personally. Guaranteed results, pound promises presented as typical, "medically supervised" language where no clinician sees patients, and any implication that a compounded GLP-1 is FDA-approved all sit in the danger zone — compounded drugs are not approved. Using a brand name while dispensing a compounded preparation is a misrepresentation; if you dispense compounded semaglutide, say so. Photos and testimonials must be genuine and consented in writing, and an intake page promising approval in minutes advertises the absence of an evaluation.

Beyond licensing

Professional liability carriers commonly exclude acts outside the insured's scope and unlawful acts, so an out-of-scope prescription can be both the event causing a claim and the reason it is denied. Add Consumer Protection Act exposure under chapter 19.86 RCW for deceptive marketing, negligence liability, and the effect of a published disciplinary notice in a market where patients search a clinician's name before booking. The Department of Health has also convened an interagency Medical Spa and Esthetic Services Work Group to map medical esthetic services against licensure and supervision requirements, so the seams described here are visible to the agencies too.

Summary: Building a Compliant Washington GLP-1 Program

Put the pieces together and a defensible Washington programme has a recognisable shape. Use this build order.

1. Decide who the prescriber is, and verify the credential — an ARNP with prescriptive authority runs the entire clinical arc independently, so check the authority itself, not the title.
2. If the prescriber is a PA, read the practice agreement and confirm it covers metabolic and obesity management.
3. Fix sourcing before marketing. Approved product through a licensed pharmacy is cleanest; patient-specific compounding needs a documented need per patient, and every pharmacy checked on the Washington credential search — including nonresident licensure under RCW 18.64.350 to 18.64.400.
4. Require a real prescriber evaluation every time, in person or by compliant synchronous telehealth, with consent and identity verification documented. No questionnaire approvals, no standing orders, no retroactive signing.
5. Write a screening protocol that reads like clinical decision rules, with explicit eligibility criteria, a contraindication review, and named referral-out triggers — and put a documented clinician decision behind every titration step.
6. Keep the three files current — clinical, sourcing, structural — and audit your marketing against your charts so the claim and the record describe the same drug from the same source.

Rather than assemble the protocols, screening criteria, consent forms, and monitoring schedules from scratch, our library of ready-to-use med spa compliance SOPs covers the documentation behind every step above.

Washington GLP-1 compliance in plain terms

• ARNPs hold full practice authority under RCW 18.79.250 — prescriptive authority under WAC 246-840-410 is a separate credential to verify.
• PAs prescribe through a participating physician; RNs, LPNs, and MA-Cs may only administer on a patient-specific order.
• WAC 246-919-606 governs cosmetic procedures, not weight loss — do not cite it in a GLP-1 protocol.
• No in-person exam is required for a non-controlled prescription; telehealth meets the same standard of care.
• Only patient-specific compounding with a documented individual need survives the end of shortage-era discretion.
• Out-of-state pharmacies shipping in need nonresident licensure under RCW 18.64.350 to 18.64.400.
• Unlicensed practice draws fines up to $1,000 per day under RCW 18.130.190, and is a class C felony on repeat.

For the injector-scope companion to this guide, see who can inject Botox in Washington, and browse the Washington med spa compliance hub for the rest of the cluster.

This article is for informational purposes only and does not constitute legal or medical advice, and nothing in it is a recommendation about the care of any patient. It describes regulatory requirements; it does not tell any clinician how to treat. Washington prescribing, delegation, telemedicine, and pharmacy rules are administered by several agencies — the Washington Medical Commission, the Washington State Board of Nursing (formerly the NCQAC), the Pharmacy Quality Assurance Commission, and the Department of Health — and federal compounding policy for GLP-1 drugs has changed repeatedly and remained partly unresolved as of publication. Where Washington's or the FDA's position is genuinely unsettled, we have said so rather than guessed. Confirm current requirements with the relevant agency and consult a Washington healthcare attorney before making prescribing, staffing, or sourcing decisions.

Frequently Asked Questions